Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,980.20 | 38.70 | 0.43% |
| CAC 40 | 7,744.41 | 53.81 | -0.69% |
| DAX 40 | 24,041.90 | 265.90 | -1.09% |
| Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
| FTSE 100 | 9,023.81 | 10.82 | 0.12% |
| HKSE | 25,280.34 | 150.31 | 0.60% |
| NASDAQ | 20,892.69 | 81.49 | -0.39% |
| Nikkei 225 | 40,815.89 | 1,040.97 | 2.62% |
| NZX 50 Index | 12,738.81 | 94.93 | -0.74% |
| S&P 500 | 6,309.62 | 4.02 | 0.06% |
| S&P/ASX 200 | 8,717.30 | 40.10 | 0.46% |
| SSE Composite Index | 3,596.52 | 14.66 | 0.41% |